Skip to main content

Table 2 Laboratory profile, imaging, and histopathology of patients with ILD and a positive anti-Ro52 antibody

From: Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody

Variable All patients
n = 73
Stratified by Autoantibodies
Isolated Anti-Ro52
n = 50
Anti-Ro52 plus myositis-specific autoAb
n = 23
Raw p-value Adjusted p-value*
Anti-Ro52 titer (nl < 20 Units), median [interquartile range] 59 [31–122] 44.5 [28–98] 108 [41–140] 0.01 0.25
ANA, n (%)     0.07 0.85
 Negative 13 (17.8%) 9 (18%) 4 (17.4%)   
 Positive titer <1:320 31 (42.5%) 17 (34%) 14 (60.9%)   
 Positive titer > = 1:320 29 (39.7%) 24 (48%) 5 (21.7%)   
Creatine kinase (nl < 400 U/L), median [range] 110 [13–13,965] (n = 63) 102 [13–13,965] (n = 42) 119 [21–1774] (n = 21) 0.73 1.0
Aldolase (nl < 7.7 U/L), median [range] 7.90 [3.8–273] (n = 67) 8.0 [3.9–273] (n = 45) 7.15 [3.8–45] (n = 22) 0.25 1.0
SS-A ELISA positive, n (%) 9 (14.3%) (n = 63) 8 (18.2%) (n = 44) 1 (5.3%) (n = 19) 0.26 1.0
Positive cytoplasmic Ab, n (%) 17 (23.3%) 5 (10%) 12 (52.2%) <0.0001 0.002
Dominant radiographic pattern, n (%)     0.93 1.0
 OP 25 (34.3%) 16 (32%) 9 (39.1%)   
 NSIP 14 (19.2%) 10 (20%) 4 (17.4%)   
 UIP 13 (17.8%) 8 (16%) 5 (21.7%)   
 Mixed OP/NSIP 10 (13.7%) 8 (16%) 2 (8.7%)   
 HP 4 (5.5%) 3 (6%) 1 (4.4%)   
 Sarcoid 2 (2.7%) 1 (2%) 1 (4.4%)   
 LIP 1 (1.4%) 1 (2%) 0 (0%)   
 DAD 1 (1.4%) 1 (2%) 0 (0%)   
 PPFE 1 (1.4%) 1 (2%) 0 (0%)   
 Infection/aspiration 1 (1.4%) 1 (2%) 0 (0%)   
 Other 1 (1.4%) 0 (0%) 1 (4.4%)   
Fibrosis present, n (%) 37 (50.7%) 25 (50%) 12 (52.2%) 0.86 1.0
Lung biopsy pathology, n (%)     0.07 0.85
 OP 7 (9.6%) 5 (10%) 2 (8.7%)   
 NSIP 3 (4.1%) 3 (6%) 0 (0%)   
 UIP 1 (1.4%) 0 (0%) 1 (4.4%)   
 Mixed OP/NSIP 3 (4.1%) 0 (0%) 3 (13%)   
 HP 1 (1.4%) 1 (2%) 0 (0%)   
 Sarcoid 1 (1.4%) 1 (2%) 0 (0%)   
 No biopsy 57 (78.1%) 40 (80%) 17 (73.9%)   
  1. *Corrected for multiple comparisons using the step-down Sidak method